6 Feb 2014 16:06
For immediate release | 6 February 2014 |
ABCAM PLC
("Abcam" or "the Company")
Block Admission Return
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
Name of Company | Abcam plc | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Names of Schemes | Abcam EMI Scheme Abcam SAYE Scheme Abcam 2005 Share Option Scheme Abcam Share Incentive Plan Abcam Company Share Option Plan Abcam Long Term Incentive Plan Annual Bonus Plan | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Period of Return (from/ to) | 7 December 2007 - 6 February 2014 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of scheme issues and current balance of securities not yet issued under each scheme during the period 7 December 2007 - 6 February 2014:
† The number of shares issued before the Company's 5 for 1 share split in November 2010 have been adjusted to take account of the share split.
* The security type for all securities listed above is Ordinary shares of 0.2p each.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Jeff Iliffe, Chief Financial Officer
| |
Numis Securities - Nominated Adviser & Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade - Nominated Adviser | |
James Black - Corporate Broking
| |
Peel Hunt LLP - Joint Broker | + 44 (0) 20 7418 8900 |
Andy Crossley - Corporate Broking
| |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes for editors:
About Abcam plc
Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.
Abcam is committed to providing scientists with access to the correct reagents and tools for their research. The Company's catalogue currently comprises more than 127,000 products and is continually evolving to meet customer needs. The range offered includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam products are supported with detailed, up-to-date and unbiased data on our website.
Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices and ships to over 100 countries. The Company was founded in 1998, and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange (AIM: ABC).
To find out more, please visit www.abcam.com